Abstract |
This was a retrospective observational study in a pediatric intensive care unit, in which 19 patients received levosimendan. There were no adverse events attributable to levosimendan and no instances where the clinical condition worsened after administration. Arterial lactate levels decreased significantly following levosimendan administration during cardiopulmonary bypass for anticipated low cardiac output. In those with established low cardiac output, trends toward improved hemodynamics were seen, with heart rate reduction, an increase in mean blood pressure, a reduction in arterial lactate, and reduced conventional inotrope use. Levosimendan was safely used in a small number of pediatric patients with established low cardiac output state who demonstrated improved hemodynamics and tissue perfusion, with a tendency to reduced conventional inotrope usage, and this warrants its evaluation as an inotrope in the pediatric population.
|
Authors | Jonathan R Egan, Andrew J B Clarke, Stephen Williams, Andrew D Cole, Julian Ayer, Stephen Jacobe, Richard B Chard, David S Winlaw |
Journal | Journal of intensive care medicine
(J Intensive Care Med)
2006 May-Jun
Vol. 21
Issue 3
Pg. 183-7
ISSN: 0885-0666 [Print] United States |
PMID | 16672640
(Publication Type: Journal Article)
|
Chemical References |
- Cardiotonic Agents
- Hydrazones
- Pyridazines
- Simendan
|
Topics |
- Adolescent
- Cardiac Output, Low
(drug therapy, etiology)
- Cardiotonic Agents
(administration & dosage, pharmacology, therapeutic use)
- Child
- Child, Preschool
- Drug-Related Side Effects and Adverse Reactions
- Heart Defects, Congenital
(complications, drug therapy)
- Hemodynamics
(drug effects)
- Humans
- Hydrazones
(administration & dosage, pharmacology, therapeutic use)
- Infant
- Infant, Newborn
- Infusions, Intravenous
- Pyridazines
(administration & dosage, pharmacology, therapeutic use)
- Retrospective Studies
- Simendan
|